Study Title

68Ga-MY6349 a Clinical Study of the Diagnostic Efficacy of PET/CT for Tumours of Epithelial Origin

Study Details

Description:

This is a study using an autocontrol approach, enrolling 40 patients with tumours of epithelial origin, who underwent 68Ga- MY6349 and 68Ga-PSMA/18F-FDG PET/CT imaging of patients with tumours of epithelial origin to compare the ability to diagnose, stage and monitor recurrence of tumours of epithelial origin using the pathological findings as the gold standard.

Sponsor:

Xijing Hospital

Contacts:

Ying Guo

guoying01192022@163.com

0086+15991459177

Government Study Link:

NCT06770478 - Click here to see study on

ClinicalTrials.gov

Drug Details

68Ga- MY6349
Isotope(s):
    GALLIUM-68
    Radioisotope: Ga-68
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 68 minutes
    Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
    Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
    Range: N/A
    Decay Daughters: Zn68 (Stable)
    Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
  • GALLIUM-68
Target(s):
  • Trop-2

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468